V
Vita Therapeutics
Dedicated scientists striving to advance treatments in multiple indications in cell therapy platform
About Vita Therapeutics
Vita Therapeutics is a pioneering cell engineering company leveraging induced pluripotent stem cell (iPSC) technology to develop specialized cell types aimed at replacing defective cells in patients. Operating in the biotechnology sector, Vita Therapeutics primarily serves patients suffering from genetic disorders, with a focus on conditions like limb girdle muscular dystrophy (LGMD2A). The company’s business model revolves around creating universal iPSC lines that can be used to generate cells and tissues for restoring normal biological functions. These engineered cells are designed to evade immune system attacks, enabling rapid and cost-effective treatments for diseases that are currently incurable. Vita Therapeutics generates revenue through clinical trials and partnerships with healthcare providers and pharmaceutical companies. The company is progressing its lead program, VTA 100, and is set to recruit 15 patients for its first-in-human clinical trial. By banking stem cells and creating gene-corrected healthy cells, Vita Therapeutics aims to support true regeneration and cure diseases at their root.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Baltimore, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 72.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Vita Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2022 | $31M | $160M | Cedars-Sinai · Cambrian BioPharma · SOLVE FSHD · TEDCO | ↗ |
| SERIES AOther financing | Jun 2021 | $32M | $128M | Early Light Ventures · Kiwoom Investment · SCM Lifescience · Cambrian BioPharma | — |
Growth signals
Latest recorded traffic for Vita Therapeutics is 520 monthly website visits, down 74% over the last three months. Vita Therapeutics's team declined 11.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
Maryland Stem Cell Research Fund
Series A8 investors entered at this stage
Cambrian BioPharma- EVEarly Light Ventures
- KIKiwoom Investment
SCM Lifescience
SOLVE FSHD
Cedars-Sinai
TEDCO
Riptide Ventures
Other known investors1 additional known investor
Johns Hopkins University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vita Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vita Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.